Introduction

Neutrophils are the workhorses of the innate immune system. They are the most common type of white blood cell, the first to reach sites of infection, and the cell at the center of the body's earliest antibacterial response.

This article walks through the morphology, life cycle, function, and clinical relevance of neutrophils, then covers the most important disorders, the laboratory tests used to evaluate them, and recent updates to how clinicians interpret neutrophil counts.

Neutrophil Morphology

A mature neutrophil is about 12–15 µm across, slightly larger than a red blood cell. Two features make it recognizable on a blood smear.

Nuclear segmentation. The nucleus is divided into 2 to 5 lobes connected by thin chromatin strands. The lobe count increases as the cell ages, and more than 5 lobes (termed hypersegmentation) is a classic clue to vitamin B12 or folate deficiency.

Cytoplasmic granules. The cytoplasm is packed with three granule populations, each with a job:

• Primary (azurophilic) granules contain myeloperoxidase, defensins, and lysosomal enzymes. They are the main weapons used inside the phagosome to digest swallowed microbes.
• Secondary (specific) granules carry lactoferrin, lysozyme, and alkaline phosphatase, which support bacterial killing and amplify inflammation.
• Tertiary (gelatinase) granules release gelatinase and other matrix metalloproteinases, helping neutrophils chew through tissue to reach infection sites.

The cytoplasm also contains glycogen stores, which fuel the cell when it operates in oxygen-poor inflamed tissue.

Neutrophil Lifespan

Neutrophils live fast. Most of their existence is spent maturing in the bone marrow before a brief, busy career in the body.

• Bone marrow (maturation and storage): about 10 days
• Bloodstream: less than 24 hours
• Tissue: 2–3 days, after which they undergo apoptosis and are cleared by macrophages

This short circulating half-life is why ANC drops so quickly after bone marrow injury from chemotherapy: there is essentially no peripheral reserve to fall back on.

Absolute Neutrophil Count (ANC)

The absolute neutrophil count (ANC) is the actual number of neutrophils per microliter of blood, not just the percentage. Because the percentage alone can be misleading when the total white cell count is abnormal, the ANC is the number clinicians use to judge infection risk.

How it is calculated:

ANC = Total WBC × (% segmented neutrophils + % bands) / 100

A typical adult reference range is 1.5 to 7.5 × 10⁹/L, with children and infants tending slightly higher [9]. Laboratory ranges vary, so always interpret a result against the issuing lab's reference interval.

Duffy-Null Associated Neutrophil Count (DANC)

For decades, "ethnic variation" in neutrophil counts was vaguely acknowledged. We now know the cause: a homozygous variant in the ACKR1 gene promoter that turns off Duffy antigen expression on red cells. People with this phenotype, known as Duffy-null, have lower circulating neutrophil counts because more neutrophils are stored in the marginated pool and tissues rather than the bloodstream. Total body neutrophil stores and function are entirely normal.

The phenotype is common in people of sub-Saharan African or Middle Eastern ancestry, affecting roughly 70% of Black individuals in the United States. Median ANC in DANC sits around 2.8 × 10⁹/L compared with about 4.7 × 10⁹/L in non-DANC populations [1]. This matters: patients with DANC have historically been mislabeled as neutropenic, excluded from clinical trials, had unnecessary bone marrow biopsies, and received reduced chemotherapy doses despite no increased infection risk [2,3]. Awareness of DANC is now considered a health-equity priority by the American Society of Hematology.

Other Factors Affecting Counts

Age, sex, pregnancy, smoking, recent exercise, time of day, and laboratory method all influence neutrophil counts. Interpret any borderline result in context, ideally with a repeat sample.

Neutrophil Function

Neutrophils have four main weapons. They often work together, but each can also fire independently.

Phagocytosis

Phagocytosis is the signature neutrophil function. It unfolds in five steps:

1. Chemotaxis. The neutrophil follows chemical gradients (IL-8, complement C5a, bacterial peptides) toward the infection site.
2. Adherence. It binds the pathogen, often after the microbe has been coated with antibodies or complement (a process called opsonization).
3. Ingestion. Pseudopods wrap around the microbe and seal it inside a phagosome.
4. Phagosome–lysosome fusion. The phagosome merges with granules, exposing the microbe to enzymes.
5. Killing and digestion. Reactive oxygen species and granule contents finish the job.

The Oxidative Burst

The oxidative burst is a rapid surge of reactive oxygen species (ROS) including superoxide, hydrogen peroxide, hypochlorous acid generated by the NADPH oxidase complex. ROS damage microbial membranes, proteins, and DNA. The same machinery can also fire in response to inflammatory cytokines or bacterial fragments without phagocytosis.

Degranulation

Granule contents can be released into the phagosome to kill an internalized microbe, or directly into the extracellular space to drive inflammation and tissue repair.

Neutrophil Extracellular Traps (NETs)

In a process called NETosis, neutrophils unspool their own DNA into the extracellular space, decorating it with histones and antimicrobial proteins. The resulting web traps and kills pathogens. While protective in infection, NETs have a darker side: excessive or poorly cleared NETs are now firmly linked to venous and arterial thrombosis, lupus, ANCA-associated vasculitis, severe COVID-19, and cancer progression and metastasis [5].

NET biology has become one of the most active areas in hematology research, with several drugs in development that target NET formation or breakdown. These include peptidylarginine deiminase 4 (PAD4) inhibitors, which prevent the chromatin decondensation required for NETosis, and therapeutic DNases designed to dismantle existing NETs [12].

Role in Inflammation

Neutrophils help recruit more immune cells, increase vascular permeability so plasma proteins can reach tissues, and release cytokines that amplify the immune response. When their activity is excessive or prolonged, however, they damage healthy tissue — a feature of conditions ranging from acute lung injury to inflammatory bowel disease.

Neutrophils in Cancer Biology 

Beyond infection and inflammation, neutrophils are central players in the tumor microenvironment. Tumor-associated neutrophils (TANs) are now recognized to polarize into two distinct phenotypes: N1 (anti-tumor) and N2 (pro-tumor). While N1 neutrophils attack tumor cells and recruit T-cells, tumors secrete factors that drive neutrophils into the N2 state. N2 TANs actively suppress the immune system, promote angiogenesis, and facilitate metastasis. Modulating neutrophils from the N2 to the N1 phenotype is currently a major focus of immuno-oncology research [11].

Granulopoiesis

Granulopoiesis is the bone marrow process that produces granulocytes (neutrophils, eosinophils, basophils) from hematopoietic stem cells. It takes about 5–6 days from the earliest precursor to a mature, released neutrophil, and is driven by cytokines including stem cell factor (SCF), interleukin-3 (IL-3), and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The stages, in order:

• Myeloblast. Large cell, large round nucleus with fine chromatin and visible nucleoli, basophilic agranular cytoplasm.
• Promyelocyte. Slightly larger than the myeloblast, coarser chromatin, first appearance of primary (azurophilic) granules.
• Myelocyte. Smaller, indented nucleus, secondary (specific) granules appear. Last stage capable of cell division.
• Metamyelocyte. Kidney-shaped nucleus, mixed primary and secondary granules; cell division has stopped.
• Band neutrophil. Elongated, unsegmented nucleus. Bands appearing in peripheral blood (a "left shift") suggest the marrow is releasing immature cells, often in response to severe infection.
• Segmented (mature) neutrophil. The 2- to 5-lobed cell described above, now fully equipped and released into circulation.

Benign Disorders of Neutrophils

Neutrophilia (High Neutrophil Count)

Neutrophilia is a count above the upper reference limit. Common causes include:

Most reactive neutrophilia resolves with the underlying trigger. Persistently elevated counts above 50 × 10⁹/L, or counts associated with anemia, thrombocytopenia, or splenomegaly, warrant evaluation for a myeloproliferative neoplasm [8].

Neutropenia (Low Neutrophil Count)

Neutropenia is conventionally defined as an ANC below 1.5 × 10⁹/L, with severe neutropenia below 0.5 × 10⁹/L. Causes fall into three groups:

Febrile Neutropenia

Febrile neutropenia is the most feared complication of chemotherapy. It is defined as a single oral temperature ≥38.3°C (or ≥38.0°C sustained for an hour) in a patient with an ANC below 500/µL, or expected to fall there [6]. Because severely neutropenic patients cannot mount a normal inflammatory response, infections can be silent and deteriorate within hours.

Management principles:

• Take blood cultures and start broad-spectrum intravenous antibiotics within one hour.
• Risk-stratify with the MASCC or CISNE score. High-risk patients are admitted; selected low-risk patients can be managed outpatient with oral antibiotics.
• Empiric monotherapy with an antipseudomonal beta-lactam (cefepime, meropenem, or piperacillin-tazobactam) is standard. Vancomycin is added only for specific indications such as suspected line infection or hemodynamic instability.

Prevention and Supportive Care

For chemotherapy regimens with a >20% risk of febrile neutropenia, prophylactic granulocyte colony-stimulating factor (G-CSF like filgrastim or pegfilgrastim) is recommended to shorten the neutropenic period. Patients are counseled on hand hygiene, avoiding sick contacts, food safety (no raw or undercooked items), and prompt reporting of any fever [4,6].

Pelger-Huët anomaly

Pelger-Huët anomaly is a benign inherited condition (autosomal dominant) in which neutrophil nuclei are bilobed or peanut-shaped instead of multilobed. Cell function is normal and patients are not at increased infection risk. The same morphology can appear as a pseudo–Pelger-Huët change in myelodysplastic syndromes, certain infections, and after some medications. When seen unexpectedly, ruling out an underlying marrow disorder is important.

Reactive Morphological Changes

Stressed neutrophils show characteristic peripheral smear findings:

• Toxic granulation — coarse dark granules in cytoplasm, seen in severe bacterial infection and sepsis.
• Döhle bodies — pale blue cytoplasmic inclusions of retained ribosomal RNA.
• Cytoplasmic vacuolation — vacuoles generally indicate active phagocytosis in severe infection. However, unexplainable, prominent vacuolation in myeloid precursors and mature neutrophils particularly in older males with severe systemic inflammation, is a classic morphological clue for VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, a severe autoinflammatory disorder caused by somatic mutations in the UBA1 gene [10].
• Left shift — increased band forms and earlier precursors in blood, signaling marrow demand.
• Hypersegmentation — more than 5 nuclear lobes, classic for B12 or folate deficiency.

Neutrophils in Specific Diseases

The conditions below are not benign and are usually classified as primary immunodeficiencies.

Chronic Granulomatous Disease (CGD)

CGD is an inherited defect in the NADPH oxidase complex. Neutrophils can still engulf microbes but cannot generate the reactive oxygen species needed to kill them. Patients suffer recurrent severe infections, particularly with catalase-positive organisms such as Staphylococcus aureus, Aspergillus, Serratia, and Burkholderia. Diagnosis uses the dihydrorhodamine (DHR) flow cytometry test, and management includes lifelong antimicrobial prophylaxis, interferon-gamma, and in select cases, hematopoietic stem cell transplantation.

May-Hegglin Anomaly

A rare autosomal dominant disorder featuring large platelets, mild-to-moderate thrombocytopenia, and Döhle-like inclusions in neutrophils. Most patients are asymptomatic, though bleeding can occur if platelet counts fall.

Chediak-Higashi Syndrome

A rare autosomal recessive disorder caused by LYST mutations. Neutrophils contain giant fused granules visible on smear, and lysosomal trafficking is impaired across many cell types. Patients suffer recurrent infections, partial oculocutaneous albinism, and a high risk of a fatal "accelerated phase" resembling hemophagocytic lymphohistiocytosis. Stem cell transplant is the only curative option.

Severe Congenital Neutropenia and Cyclic Neutropenia

Severe congenital neutropenia (SCN) is most commonly caused by ELANE mutations and presents in infancy with recurrent bacterial infections and chronic ANC <0.5 × 10⁹/L. Cyclic neutropenia, also often ELANE-related, produces predictable neutrophil dips every 21 days. Both respond well to long-term G-CSF therapy, and current European guidelines outline surveillance for the small but real risk of progression to myelodysplastic syndrome or acute myeloid leukemia [4].

Laboratory Tests for Neutrophil Evaluation

Laboratory tests play a crucial role in assessing neutrophil numbers, function, and morphology. 

Basic Tests

• Complete Blood Count (CBC) with Differential: This is the initial test to evaluate neutrophil count, whether high neutrophil or low neutrophil count, percentage, and morphology.
• Peripheral Blood Smear: Essential for morphology: segmentation, granulation, inclusions, immature forms.

Further Evaluation

• Bone Marrow Aspiration and Biopsy: Assesses production, maturation arrest, infiltration, and dysplasia.
• Flow Cytometry / Immunophenotyping: Identifies abnormal cell populations and confirms specific disorders (e.g., DHR test for CGD).
• Neutrophil Function Tests: Phagocytosis, oxidative burst, and chemotaxis assays for suspected primary neutrophil disorders.
• Genetic Testing: Clinical practice has largely shifted to comprehensive Next-Generation Sequencing (NGS) myeloid panels. These panels simultaneously evaluate for inherited germline mutations (e.g., ELANE, HAX1, G6PC3 in severe congenital neutropenia) as well as somatic mutations linked to clonal hematopoiesis of indeterminate potential (CHIP) or early myelodysplastic syndromes (MDS) [13].
• Duffy phenotype/genotype testing: Increasingly considered in patients with isolated mild neutropenia and African or Middle Eastern ancestry, to avoid unnecessary investigation [1,2].

Specialized Antibody Tests

Granulocyte immunofluorescence test (GIFT) and granulocyte agglutination test (GAT) detect anti-neutrophil antibodies (anti-HNA), important in autoimmune neutropenia and transfusion-related acute lung injury (TRALI).

Frequently Asked Questions (FAQs)

What are neutrophils and what do they do?

Neutrophils are the most common white blood cell in human blood and the first responders of the immune system. They detect bacterial and fungal infections, travel to the site, and destroy invaders through phagocytosis, degranulation, the oxidative burst, and the release of DNA-based traps called NETs.

What is a normal neutrophil count, and what counts as low?

In healthy adults, neutrophils typically range from 1.5 to 7.5 × 10⁹/L. A count below 1.5 × 10⁹/L is generally considered neutropenia, though some healthy individuals particularly those of African or Middle Eastern ancestry with the Duffy-null phenotype have baseline counts in this range without any increased infection risk. Severe neutropenia (<0.5 × 10⁹/L) is clinically dangerous and warrants close monitoring.

Why is my neutrophil count high?

A high neutrophil count (neutrophilia) most often signals a bacterial infection, but it also rises with acute inflammation, tissue injury, physical or emotional stress, pregnancy, smoking, and certain medications including corticosteroids. Very high counts can sometimes indicate a bone marrow disorder such as chronic myeloid leukemia.

Why are neutrophils low after chemotherapy, and how is it managed?

Chemotherapy targets fast-dividing cells, including bone marrow precursors that produce neutrophils. The result is a predictable drop in ANC, usually 7 to 14 days after a treatment cycle. Management includes infection prevention, prompt evaluation of any fever, empiric broad-spectrum antibiotics for febrile neutropenia, and prophylactic G-CSF (filgrastim or pegfilgrastim) for regimens with a febrile neutropenia risk above 20%.

What is febrile neutropenia and why is it an emergency?

Febrile neutropenia is a single oral temperature of 38.3°C (or 38.0°C sustained) in a patient with an ANC below 500/µL. It is a medical emergency because patients can deteriorate within hours; standard care is immediate hospital evaluation, cultures, and empiric intravenous antibiotics within one hour of presentation in high-risk cases.

What are neutrophil extracellular traps (NETs)?

NETs are web-like structures made of DNA, histones, and antimicrobial proteins released by neutrophils to immobilize and kill pathogens. While useful in infection, excessive or poorly cleared NETs are now linked to harmful processes including blood clot formation, autoimmune diseases such as lupus, severe COVID-19, and cancer progression.

 Glossary of Related Medical Terms

• Absolute neutrophil count (ANC): The actual number of neutrophils in a microliter of blood, calculated from the total white cell count and the neutrophil percentage.
• Chemotaxis: Movement of a cell toward a chemical signal, used by neutrophils to find infection sites.
• Degranulation: The release of antimicrobial enzymes and proteins stored in neutrophil granules.
• Duffy-null phenotype: A common genetic variant (in the ACKR1 gene) that lowers baseline neutrophil counts without increasing infection risk.
• Febrile neutropenia: Fever in a patient with a very low neutrophil count, treated as a medical emergency in cancer care.
• Granulopoiesis: The bone marrow process that produces granulocytes, including neutrophils.
• G-CSF (granulocyte colony-stimulating factor): A growth factor (filgrastim, pegfilgrastim) given to stimulate neutrophil production.
• NETosis: A form of cell death in which neutrophils release web-like DNA traps (NETs) to capture pathogens.
• Neutropenia: A lower-than-normal neutrophil count, raising infection risk.
• Neutrophilia: A higher-than-normal neutrophil count, typically from infection, inflammation, or stress.
• Oxidative burst: A rapid release of reactive oxygen species used by neutrophils to kill ingested pathogens.
• Phagocytosis: The engulfment and destruction of pathogens by immune cells.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Merz, L. E., Osei, M. A., Story, C. M., Freedman, R. Y., Smeland-Wagman, R., Kaufman, R. M., & Achebe, M. O. (2023). Development of Duffy Null-Specific Absolute Neutrophil Count Reference Ranges. JAMA, 329(23), 2088–2089. https://doi.org/10.1001/jama.2023.7467
2. Tsiamita, O., Aiken, L., Badat, M., Lowe, G., Oyesanya, F., Wolf, S., Merz, L. E., Hantel, A., & Hibbs, S. P. (2025). Medical haematology trial eligibility and the Duffy null-associated neutrophil count: A cross-sectional study. HemaSphere, 9(10), e70236. https://doi.org/10.1002/hem3.70236
3. Hibbs, S. P., Aiken, L., Vora, K., Mowete, C., Merz, L. E., Apea, V., Sloan, J. M., Lathan, C. S., Abel, G. A., & Hantel, A. (2024). Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count. JAMA network open, 7(9), e2432475. https://doi.org/10.1001/jamanetworkopen.2024.32475
4. Fioredda, F., Spanoudakis, M., Skokowa, J., Tamary, H., Farruggia, P., Almeida, A., Guardo, D., Palmblad, J., Höglund, P., Touw, I.P., Zeidler, C., Warren, A.J., Csenar, M., Skoetz, N., Castagnola, E., Ricci, E., Dale, D.C., Newburger, P.E., Welte, K., Papadaki, H.A. and Dufour, C. (2025), European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action based on a systematic evidence review. HemaSphere, 9: e70113. https://doi.org/10.1002/hem3.70113
5. Wang, H., Kim, S. J., Lei, Y., Wang, S., Wang, H., Huang, H., Zhang, H., & Tsung, A. (2024). Neutrophil extracellular traps in homeostasis and disease. Signal transduction and targeted therapy, 9(1), 235. https://doi.org/10.1038/s41392-024-01933-x
6. Stohs, E. J., Abbas, A., & Freifeld, A. (2024). Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. Transplant infectious disease : an official journal of the Transplantation Society, 26(2), e14236. https://doi.org/10.1111/tid.14236
7. Rout P, Reynolds SB, Zito PM. Neutropenia. [Updated 2024 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507702/
8. Tahir N, Zahra F. Neutrophilia. [Updated 2023 Apr 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570571/
9. Kaushansky, K., Prchal, J. T., Levi, M. M., Kipps, T. J., Roberts, I., Thein, S. L., & FiPersio, J. F. (2026). Williams Hematology (11th ed.). McGraw-Hill Education.
10. Beck, D. B., Ferrada, M. A., Sikora, K. A., Ombrello, A. K., Collins, J. C., Pei, W., Balanda, N., Ross, D. L., Ospina Cardona, D., Wu, Z., Patel, B., Manthiram, K., Groarke, E. M., Gutierrez-Rodrigues, F., Hoffmann, P., Rosenzweig, S., Nakabo, S., Dillon, L. W., Hourigan, C. S., Tsai, W. L., … Grayson, P. C. (2020). Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. The New England journal of medicine, 383(27), 2628–2638. https://doi.org/10.1056/NEJMoa2026834
11. Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020). Neutrophil diversity and plasticity in tumour progression and therapy. Nature reviews. Cancer, 20(9), 485–503. https://doi.org/10.1038/s41568-020-0281-y
12. Mutua, V., & Gershwin, L. J. (2021). A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. Clinical reviews in allergy & immunology, 61(2), 194–211. https://doi.org/10.1007/s12016-020-08804-7
13. Skokowa, J., Dale, D. C., Touw, I. P., Zeidler, C., & Welte, K. (2017). Severe congenital neutropenias. Nature reviews. Disease primers, 3, 17032. https://doi.org/10.1038/nrdp.2017.32